Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Average Recommendation of “Moderate Buy” by Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has been assigned an average rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $173.07.

Several brokerages recently issued reports on JAZZ. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company reduced their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Robert W. Baird dropped their target price on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research report on Thursday, August 1st. UBS Group reduced their price target on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 2nd. Finally, Morgan Stanley decreased their price target on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a research note on Friday, July 12th.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $109.08 on Wednesday. The company has a market cap of $6.88 billion, a PE ratio of 22.49, a price-to-earnings-growth ratio of 1.31 and a beta of 0.57. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The stock has a 50-day moving average price of $110.96 and a 200-day moving average price of $110.89. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $137.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. As a group, equities analysts forecast that Jazz Pharmaceuticals will post 16.03 earnings per share for the current fiscal year.

Insider Activity

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Rise Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 203 shares in the last quarter. Versant Capital Management Inc lifted its stake in Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 269 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $29,000. EverSource Wealth Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 97 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.